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frequencies between different tumor areas of morphologi-
cal homogeneous tumors. We conclude that genetic hetero-
geneity in morphologically homogeneous colorectal can-
cer is an observable, but underreported event. Our results 
illustrate the power of in situ mutation analysis to visualize 
genetic heterogeneity directly in tumor tissue.
Keywords In situ · Padlock probe · Tumor heterogeneity · 
NGS · Colorectal cancer
Introduction
Colorectal cancer is a complex disease with greatly vary-
ing clinical responses to therapy (Ogino and Goel 2008; 
Blanco-Calvo et al. 2015). The different clinical responses 
are primarily explained by cancer cell hetereogeneity 
within a tumor mass (Misale et  al. 2014). Tumor hetero-
geneity presents as a mixture of sub-populations of cancer 
cells with different genetic alterations which may exist in 
spatially distinct areas of a tumor (Marusyk et  al. 2012; 
Bedard et al. 2013; El-Heliebi et al. 2014). These distinct 
tumor areas can harbor sub-populations of tumor cells 
which will be resistant to future therapy even before actual 
initiation of therapy (Diaz-Cano 2012; Heitzer et al. 2013). 
In the course of treatment, these cells can be enriched and 
ultimately lead to the emergence of clinical drug resist-
ance (Misale et al. 2012). Therefore, it is of great clinical 
importance to identify genetically heterogeneous tumors. 
Parallel to genetic heterogeneity, colorectal cancer mani-
fests in a variety of different morphological subtypes, such 
as glandular, mucinous, signet ring cell, and several others 
(Fleming et  al. 2012). The different morphological phe-
notypes can be found as mixtures with each other in the 
same tumor, resulting in a morphological heterogeneous 
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clones may enrich and ultimately lead to disease progres-
sion. Although ample data are available on tumors which 
are heterogeneous on a morphological level, only little is 
known about morphologically homogeneous tumors. We 
aimed to investigate if morphologically homogeneous colo-
rectal cancer can harbor a heterogeneous genetic landscape. 
We chose to microdissect six morphologically homogene-
ous colorectal carcinomas into several areas and performed 
next-generation sequencing (NGS) to identify tumors with 
genetic heterogeneity. We then applied an mRNA-based 
in  situ mutation detection technology based on padlock 
probes to localize and visualize mutations directly in the 
tumor tissue. In three out of six tumors, NGS revealed 
a high rate of variability of mutations between differ-
ent tumor areas. We selected two cases for in  situ muta-
tion detection to visualize genetic heterogeneity. In  situ 
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tumor (Fleming et  al. 2012). Vice versa, tumors display-
ing primarily with only one morphological subtype can be 
regarded as morphologically homogeneous. Nevertheless, 
concerning their genetic landscape, homogeneous tumors 
could hide several sub-clones which might not be distin-
guished by the conventional light microscopy.
Although ample data on genetic heterogeneity have been 
described (Gerlinger et  al. 2012; Nik-Zainal et  al. 2012a, 
b; de Bruin et al. 2014; Zhang et al. 2014; Sottoriva et al. 
2015), the investigated tumor tissues were not selected 
for their morphological homogeneous appearance. Data 
on the possible genetic heterogeneity of morphologically 
homogeneous tumors are currently lacking. In addition, 
these studies were based on next-generation sequencing 
(NGS), where tissues are lysed to extract nucleic acids and 
the histological context of the tissue is lost. There is a gap 
between sequencing data and spatial information. A solu-
tion to bridge the gap is the mRNA-based padlock probe 
technology (Larsson et al. 2010). Padlock probe technology 
can detect point-mutations in situ in the tissue section and 
retains the original location of the transcript. We hypoth-
esize that morphologically homogeneous tumors may har-
bor genetic heterogeneity. Therefore, the aim of this study 
was to evaluate the genetic landscape of morphologically 
homogeneous colorectal tumors by combining NGS and a 
mRNA-based in  situ approach. First, we manually micro-
dissected morphologically homogeneous tumors into 
several distinct areas. Each area was analyzed using next-
generation sequencing (NGS) to identify mutations with 
different mutation frequencies in separate tumor areas. Sec-
ond, we visualized and quantified the detected mutations by 




Approval of the institutional ethics committee was obtained 
for this study (Medical University Graz EK24-455 ex 
11/12). All methods were performed in accordance with the 
relevant guidelines and regulations.
Tumor samples
Computerized pathological reports from the Institute of 
Pathology, Medical University of Graz, Austria, were 
searched for surgical specimens of routinely reported 
colorectal cancers, resected at the Krankenhaus der Bar-
mherzigen Brüder St. Veit/Glan, Austria, between January 
2011 and January 2013. As the relevance of genetic tumor 
heterogeneity is primarily associated with the possible 
outgrowth of resistant sub-clones under tumor specific ther-
apy, only tumors eligible in principle for adjuvant therapy 
(UICC stage III or IV) were included. All tumors were clas-
sified as invasive and all but one of these tumors displayed 
regional lymph node metastasis. Patients who had received 
neo-adjuvant treatment for rectal cancer were excluded 
from the study. Thus, 39 colorectal cancers were included 
for further evaluation. All tumors were formaldehyde 
(4% m/V buffered solution)-fixed and paraffin-embedded 
(FFPE) in their entirety. FFPE tissues were provided by the 
Biobank of the Medical University of Graz, Austria. Hema-
toxylin and eosin (HE) stained slides were evaluated for a 
homogeneous morphological appearance across the whole 
tumor area, without distinct foci delimitable on comparison 
with the surrounding tumor tissue by two pathologists (SJ, 
CV). Patterns of differentiation were based on the morpho-
logical patterns described for the special subtypes of colo-
rectal carcinoma according to the “WHO Classification of 
Tumors of the Digestive System” such as mucinous, sig-
net ring cell, micro papillary differentiation, etc (Bosman 
et al. 2010). The homogeneous tumors selected essentially 
demonstrated tubular, tubulopapillary, and occasionally 
cribriform architecture, which were present in similar pro-
portions across the different tumor areas, without circum-
script changes in differentiation patterns. After evaluation, 
six tumors with a homogeneous morphological appearance 
were selected (Supplementary Table 1). Five tumors were 
colon cancers and one tumor was a rectal cancer located in 
the proximal, peritonealized rectum. Serial sections with 
first and last section HE stained for topographical reference 
were obtained and tumor tissue was manually microdis-
sected (scraped off) from unstained sections with a scalpel. 
Tumor tissue was dissected from 4 equally sized areas and 
DNA extracted (Maxwell, MDxResearch System-Promega, 
Fitchburg, Wisconsin, USA).
Cell line
SW620 colon cancer cells were purchased from ATCC and 
were cultured in the media recommended by the distribu-
tor at 37 °C with 5%  CO2. Cells were tested negative for 
mycoplasma and were verified to be SW620 by STR analy-
sis using PowerPlex 16 System Kit (Promega, Mannheim, 
Germany).
Ion torrent comprehensive cancer panel‑sequencing 
of colorectal cancer tissue
Mutation analysis was performed using the Ion AmpliSeq 
Comprehensive Cancer Panel (Thermo Fisher Scientific, 
Waltham, MA, USA, Cat Nr 4477685) comprising 16,000 
amplicons which cover the whole coding region of 409 
tumor-related genes of the Wellcome Trust Cancer Gene 
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1 3
consensus. Libraries were prepared using the Ion AmpliSe-
qTM Library Kit 2.0 (Thermo Fisher Scientific) using the 
recommended amount of 10 ng DNA in each PCR reaction 
and sequencing was carried out on an Ion Proton Sequencer 
(Thermo Fisher Scientific) (Rothberg et  al. 2011). Emul-
sion PCR and sequencing runs were performed with the 
appropriate kits (Ion One Touch Template Kit v2 and Ion 
Proton 200 Sequencing Kit, Thermo Fisher Scientific) 
using Ion PI chips (Thermo Fisher Scientific). Sequenc-
ing length was set to 520 flows and yielded reads ranging 
from 70 to 150 base pairs consistent with the expected size 
range. On average, 20 million reads were obtained for each 
DNA library with consistently more than 80% of bases at 
AQ20. Data analysis was performed using the Ion Torrent 
Suite Software Plug-ins (Thermo Fisher Scientific, open 
source, GPL). Briefly, this included base calling, alignment 
to the reference genome (HG19) using the TMAP mapper 
and variant calling by a modified diBayes approach taking 
into account the flow space information. All called vari-
ants were annotated using open source software [Annovar 
(Wang et  al. 2010), SnpEff (Cingolani et  al. 2012)]. All 
coding and non-synonymous (amino acid changing) muta-
tion calls present in tumor tissue and absent in the corre-
sponding normal tissue were further evaluated and visually 
inspected in Integrative Genomics Viewer (IGV) (Robinson 
et al. 2011). Variant calls with an allele frequency greater 
than 5% in any of the samples were included in the analy-
sis and further evaluated for heterogeneity in all samples. 
Variant calls resulting from technical read errors (e.g., 
homopolymers, inadequate primer removal) or sequence 
effects (e.g., short repeat sequences) were excluded from 
the analysis.
Pyro‑sequencing
For in situ mutation detection, the tumors K229, K255, and 
K386 were identified as the best candidates, as NGS data 
indicated genetic heterogeneity. Before applying in  situ 
mutation detection, pyro-sequencing was performed of 
the tumors K229 and K386 to confirm NGS data. Pyro-
sequencing was performed using the Qiagen Pyromark 
platform with the appropriate kits and according to the 
manufacturer’s recommendations. Pyro-sequencing assays 
were designed for the DPYD (R886H) (Tumor K229) and 
FANCD2 (E912Q) (Tumor K386) mutations using the 
Pyromark Assay Design software. Detection and quantita-
tive mutation analysis were performed using the Qiagen 
Pyromark software.
MSI analysis
Microsatellite stability was assessed using the Promega 
MSI Analysis system (MD1641, Promega, Madison, USA) 
which includes fluorescently labeled primers for co-ampli-
fication of seven markers for analysis of the MSI-high 
(MSI-H) phenotype, including five nearly monomorphic 
mononucleotide repeat markers (BAT-25, BAT-26, MON0-
27, NR-21 and NR-24) and two highly polymorphic penta-
nucleotide repeat markers (Penta C and Penta D). Ampli-
fied fragments were detected using an ABI 3500 Genetic 
Analyzer.
Sample preparation for padlock probe approach
FFPE sections (5  µm) were transferred to superfrost plus 
slides (Thermo Fisher Scientific) and baked for 3 h at 60 °C. 
Before applying the in situ mutation detection method, the 
tissue sections were deparaffinized and pre-treated in 2 mg/
ml pepsin in 0.1 M HCl (Sigma) for 30 min at 37 °C. The 
digestion was stopped with DEPC-treated  H2O (DEPC-
H2O) for 5  min followed by a wash in DEPC-PBS for 
2 min. Thereafter, the tissue was dehydrated using an etha-
nol series of 70, 85, and 99.5% for 1 min each and stored at 
−80 °C until use for in situ mutation detection. One tissue 
section of the colorectal cancer samples was HE stained for 
histopathological confirmation of the diagnosis and rep-
resentation of different tumor areas. The HE stained slide 
was used for orientation prior to mutation scoring by in situ 
mutation detection. For the tumor K255, only areas 1 till 3 
were available for in situ mutation detection, as there was 
no tumor tissue left in deeper sections of the tumor block.
For cell line experiments, SW620 were seeded with 
media onto superfrost plus slides (Thermo Fisher Scien-
tific) over-night at 37 °C with 5%  CO2. Cells were then 
washed with DEPC-PBS for 2 min, fixed in 4% m/V for-
maldehyde (Labonord, Templemars, France) for 15  min, 
washed with DEPC-PBS, and then dehydrated via a graded 
ethanol series and further processed as for tissue sections.
LNA primer, padlock probe design, and detection 
probes
We designed an individualized patient-specific in situ assay 
based on the next-generation sequencing data.
The selected colorectal cancer cases were confirmed to 
carry a point mutation in the FANCD2 gene c.2734G > C 
(Tumor ID K386) (Substitution–coding) (Fanconi ane-
mia complementation group D2) and the KAT6A gene 
c.1425A > C (Tumor ID K255) (Substitution–coding) 
(Lysine Acetyltransferase 6A).
Padlock probes were designed using the CLC Main 
Workbench software (CLC Bio Workbench Version 7.6, 
Qiagen; Venlo, Netherlands) according to the guidelines 
published by Weibrecht et al. (2013). A padlock probe for 
β-actin was used as a control (Grundberg et al. 2013). The 
mRNA sequence was retrieved from the National Center 
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for Biotechnology Information [NCBI, GenBank acces-
sion number NM_033084.3 (FANCD2), NM_006766 
(KAT6A)]. Depending on genotype, the designed muta-
tion-specific padlock probes differ only in the last nucleo-
tide at the 3′-end target sequences. All padlock probes were 
ordered 5′-phosphorylated (Integrated DNA Technologies; 
Coralville, IA, USA). LNA primers were purchased from 
Exiqon (Exiqon; Vedbaek, Denmark) and detection probes 
from Biomers (Biomers; Ulm, Germany). The LNA primer, 
padlock probe, and detection probe sequences are summa-
rized in Table 1.
The specificity and sensitivity of the–wild-type padlock 
probes were first tested in the cell line SW620 which is wild 
type for FANCD2 and KAT6A (data not shown). Since the 
mutations were patient-specific, mutation padlock probes 
could not be tested on cell lines. After confirmation of the 
quality of the probes, the in situ method with wild type and 
mutation padlock probes were applied on an FFPE-tissue 
section from colorectal cancer patients.
In situ mutation detection in tissues and cell lines
All in situ reactions were performed in secure-seals hybrid-
ization chambers (Sigma). The reaction volumes for the 
tissue slides were either 50, 100, or 350 μl depending on 
sample size. The sample was rehydrated by incubating 
the wells with PBS-T [DEPC-PBS with 0.05% Tween-20 
(Sigma)] for 5 min at room temperature. In  situ reactions 
were performed with slight modifications as previously 
described (Weibrecht et al. 2013; Siwetz et al. 2016). For 
reverse transcription, 1 µM of each LNA primer (Exiqon) 
was added in the wells with 5 U/µl TranscriptMe Reverse 
Transcriptase (DNA-Gdansk; Gdansk, Poland), 1  U/µl 
RiboLock RNase inhibitor (Thermo Fisher Scientific), 
0.5 mM dNTPs (Thermo Fisher Scientific), and 0.2 µg/µl 
BSA (NEB; Ipswich, MA, USA) to the room temperature 
Reaction Buffer (DNA-Gdansk). All units mentioned are 
displayed as final concentrations. Slides were incubated 
for 3 h at 45 °C in a humid chamber. After removing the 
reaction mix, the tissue was postfixed with 3% formalde-
hyde (Sigma) in DEPC-PBS for 10  min. After postfixa-
tion, slides were washed twice by flushing the Secure-seals 
chambers with PBS-T [DEPC-PBS with 0.05% Tween-20 
(Sigma)] for 2  min each. The RNA-DNA hybrids formed 
by reverse transcription were degraded with ribonuclease 
H to make the target cDNA strands accessible for padlock 
probe hybridization. All reactions, ribonuclease H deg-
radation, padlock probe hybridization, and ligation were 
performed in the same step. Ligation reaction was car-
ried out with 0.5  U/µl Ampligase (Epicentre, Illumina, 
Table 1  Oligonucleotide sequences
Padlock probes were 5′-phosphorylated. The fluorophores of the detection oligos were 5′ conjugated
+: the following base is LNA modified; underlined: target complement sequence, bold: detection probe complement sequence
*Modified from (Grundberg et al. 2013)
Primers Sequences (5′–3′)
ACTB* C+GG+GC+GG+CG+GAT CGG CAAAG
FANCD2_LNA A+TG+GG+AA+TT+AT+GTA GTA ACA ATG 
KAT6A_LNA T+TT+CT+GC+AG+TG+CTT GTT CTT
Padlock probes Sequences (5′–3′)
plp_ACTB* AGC CTC GCC TTT GCCTTC CTT TTA CGA CCT CAA TGC ACA TGT TTG GCTCCTCTTCGCC CCG CGA 
GCA CAG
plp_FANCD2_WT AAA AGA CAT CAT TGTTCC TAG TAATCAG TAG CCG TGA CTA TCG ACTGGT TCA AAGTCA CAG GGA 
AGG AAG
plp_FANCD2_MUT AAA AGA CAT CAT TGTTTC CTT TTA CGA CCT CAA TGC TGC TGC TGT ACTACTCTTCTCA CAG GGA 
AGG AAC
plp_KAT6A_WT ATC ATG ACT GAG AAAGAAAAGT AGC CGT GAC TAT CGA CTAAT GCG TCT ATT TAG TGG AGC CCA 
CTATCTTT GGG AGC CAG GAA
plp_KAT6A_MUT ATC ATG ACT GAG AAAGAAACCT CAA TGC TGC TGC TGT ACTACAAT GCG TCT ATT TAG TGG AGC 
CTT CTATCTTT GGG AGC CAG GAC
Detection probes Sequences (5′–3′)
D1_ATTO 488 Atto 488-CCT CAA TGC ACA TGT TTG GCTCC
D2_ATTO 647N Atto 647N-AGT AGC CGT GAC TAT CGA CT
D3_ATTO 550 Atto 550-CCT CAA TGC TGC TGC TGT ACTAC
D4_Cy3 Cy3-AGT AGC CGT GAC TAT CGA CT
D5_FITC FITC-CCT CAA TGC TGC TGC TGT ACTAC
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Madison, WI, USA), 0.4  U/µl RNase H (DNA-Gdansk), 
0.2 µg/µl BSA (NEB), 0.1 µM of each padlock probe (Inte-
grated DNA Technologies), and 50 mM KCl, 20% forma-
mide (Sigma) in Ampligase buffer. The slides were incu-
bated for 30 min at 37 °C and 45 min at 45 °C in a humid 
chamber. After the ligation step, the slides were washed by 
flushing the chambers once with 1× SSC-Tween and two 
times with 2× DEPC-PBS-T for 5 min each. The washing 
steps were followed by rolling-circle amplification (RCA) 
performed with 1 U/µl phi29 DNA polymerase (Thermo 
Fisher Scientific), 0.25  mM dNTPs (Thermo Fisher Sci-
entific), 0.2 µg/µl BSA (NEB), and 5% glycerol (Sigma) in 
phi29 buffer. The incubation was carried out over-night at 
37 °C in a humid chamber. The rolling-circle amplification 
incubation was followed by two washing steps with PBS-T 
[DEPC-PBS with 0.05% Tween-20 (Sigma)]. Rolling-circle 
products (RCPs) were visualized using 0.1 µM of each cor-
responding detection probe (Biomers) in 2× SSC and 20% 
formamide (Sigma) for 30 min at 37 °C in a humid chamber 
protected from light. Slides were washed two times with 
PBS-T [DEPC-PBS with 0.05% Tween-20 (Sigma)], nuclei 
were counterstained with 5 mg/mL DAPI (Thermo Fisher 
Scientific) for 5 min at RT. After DAPI staining, the reac-
tion areas were marked at the bottom of the glass slide by 
scratching and secure-seals were removed from the slides. 
A series of 70, 85–99.5% (3  min each) ethanol was per-
formed for dehydration. The samples were mounted with 
SlowFade Gold Antifade Mountant (Thermo Fisher Sci-
entific) and stored at 4 °C protected from light until image 
analysis. A second tissue slide of normal colon tissue from 
the same patient was used for positive and negative con-
trols. As an internal positive control, LNA primers and the 
padlock probe of the ubiquitously expressed β-actin (ACTB 
gene) transcript were added to the in  situ reaction. LNA 
primers were not added to a second reaction spot as a nega-
tive control. Apart from these changes, all controls were 
treated with the same process as described above.
Image acquisition and analysis
An HE stained section of the tumor tissue was used to 
ensure correct scoring of mutations in each tumor area, and 
the same four areas which were dissected for NGS sequenc-
ing were analyzed with the in situ detection method. As a 
control, non-neoplastic colon tissue from the same patient 
was used. Quantification was performed on ten 20× micro-
scope images per area. As the tumor areas 1–4 have a dif-
ferent tumor cell content, images for quantification were 
taken within each area with a tumor cell content >80% 
to avoid bias by the surrounding stroma. Images were 
acquired using the Zeiss Observer.Z1 inverted micro-
scope (Carl Zeiss; Oberkochen, Germany) equipped with a 
120 W HXP Mercury short-arc lamp, a 2/3″ CCD camera 
(AxioCam MRm, Carl Zeiss) and an excitation and emis-
sion filter-set for visualization of DAPI, FITC, Cy3, and 
Cy5. A 20× objective (Plan-Apocromat, Zeiss) and the 
AxioVision software (Carl Zeiss, Version 4.8.2.0) were 
used for capturing the images. To ensure that all rolling-
circle products (RCPs) were imaged, Z-Stacks were com-
bined in one layer as a maximum intensity projection with 
the ZEN 2 blue software (Carl Zeiss, Version 2.0.0.0). 
The in  situ overview image was generated by stitching of 
images using a 20× objective with the ZEN software. For 
better visualization, brightness and contrast of each image 
were adjusted. For visualization of specific RCP signals in 
the whole tissue overview, fluorescent signals which were 
visible in multiple wavelengths (unspecific signals) were 
subtracted from the respective detection channels. The 
FITC, CY3, and CY5 signals with a pixel intensity ratio 
of signal/background >5 were then enlarged by 50 or 100 
pixels depending on the tissue size and number of RCP sig-
nals, and color coded to their respective transcripts using 
image editing software. For detailed quantification, signals 
with a pixel intensity ratio of signal/background >2 were 
manually inspected, counted, and false positive signals 
excluded [typically visible at multiple wavelengths (Wei-
brecht et al. 2013)].
Statistical analysis
Statistical analyses were performed using the GraphPad 
Prism software, version 6.01 (GraphPad Prism, Inc., La 
Jolla, USA) for parametric comparison of two groups. An 
unpaired T Test was applied to compare the mean of the 
mutation allele frequency of every group (area 1 to area 4) 
to the mean of the non-neoplastic control tissue. Results 
were considered statistically significant when p < 0.05 
(*p < 0.05, ***p < 0.001 and ****p < 0.0001).
Results
Detection of genetic heterogeneity in morphological 
homogeneous tumors by NGS
Mutational profiles of four separate areas of six colorectal 
carcinomas and their corresponding normal tissue were 
generated via next-generation sequencing. Comparison 
of the somatic mutation frequencies of several mutations 
over multiple tumor areas revealed in three out of six 
tumors (K229, K255 and K386) a high variability which 
was not explainable by simple differences in tumor cell 
content (Fig. 1, Supplementary Fig. 1). In the remaining 
three cases, the tumors represent genetically homogene-
ous tumors (Fig.  1, Supplementary Fig.  1). All tumors 
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were assessed for microsatellite stability and found to be 
MSI stable.
The analysis of the sequence of 409 cancer-related 
genes in multiple areas (n = 4 per tumor) of morphologi-
cal homogeneous tumors revealed a total of 34 somatic 
mutations in the cases investigated (Supplementary 
Table 2). 20 out of 34 (59%) were non-synonymous mis-
sense mutations, the remaining 14 mutations (41%) were 
either synonymous-, intronic-, or frameshift mutations. 
Further evaluation focused on samples with non-synony-
mous missense mutations which were differently distrib-
uted between the different tumor areas.
Two tumor samples with a differential mutational 
distribution between the tumor areas, which were not 
attributable to differences in tumor cell content, were re-
evaluated by pyro-sequencing. In one of the two cases, 
the DPYD mutation c.697C > A was shown to be equally 
distributed in each tumor area by pyro-sequencing (Sup-
plementary Fig.  2) arguing that technical differences 
in amplicon generation for NGS sequencing (i.e. dif-
fering amplification efficiencies of multiplexed PCR 
amplicon generation) might have been the cause for the 
observed mutant allele differences in the NGS analysis. 
However, in one case, NGS showed a different muta-
tion frequency of the FANCD2 mutation c.2734G > C 
(Substitution–coding) over the four tumor areas investi-
gated which was confirmed by pyro-sequencing (Supple-
mentary Fig. 2).
In situ mutation detection in colorectal tumor tissue
To localize the heterogeneous distribution of mutations 
in  situ and to correlate its heterogeneous distribution 
with the corresponding HE topography of the tumor, 
we performed a mRNA-based in  situ mutation detec-
tion approach based on padlock probes (Larsson et  al. 
2010). Padlock probes allow for visualization of single 
mRNA transcripts and can differentiate between two 
almost identical transcripts such as wild-type and mutant 
transcripts (Larsson et  al. 2010). In  situ mutation detec-
tion in tumor K386 showed an increased frequency of 
FANCD2 mutations from area 1 to area 4 (Figs.  2, 3a). 
In K386, all four tumor areas investigated displayed wild-
type and mutant signals, whereas area 1 showed a lower 
amount of total in situ signals. Area 3 and Area 4 showed 
an increased mutant allele frequency compared to non-
neoplastic colon control tissue (*p < 0.05, ***p < 0.001, 
respectively). The total number of mutant signals per 
area were 0.9% (3/342 signals; Mean 0.8%), 0.7% (2/295 
signals; Mean 0.8%) 6.2% (17/273 signals; Mean 6.2%), 


















































































































































































































































































































































































































































Fig. 1  Genetic landscape of three tumors after microdissection into 
four separate areas. The x-axis represents the genes with detected 
mutations. The Y-axis reflects the mutation frequency of the corre-
sponding genes in A, B, and C. a and b High degree of heterogeneity 
is indicated by different mutation frequencies in different tumor areas, 
such as FANCD2, RET, and KAT6A. c Tumor with a homogeneous 
genetic landscape evidenced by virtually identical mutation frequen-
cies in each tumor area. Variability between different areas pertains 
solely to tumor cell content. c, e, and d For a better representation 
of genetic heterogeneity, the mean mutation frequency over all four 
tumor areas was calculated and set to 1. Each individual mutation fre-
quency per area was normalized accordingly. Wide deviations from 
the mean mutation frequency, as seen in FANCD2, RET, or KAT6A, 
indicate genetic heterogeneity. Frameshift fs, stop codon = *
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4, respectively (Fig.  3a). Non-neoplastic colon tissue 
of the same patient showed a total number of FANCD2 
mutant signal of 1.5% (4/262 signals; Mean 1.6%) sug-
gesting a low unspecific technical background noise of 
the in  situ methodology, in line with the previous pub-
lished data (Larsson et  al. 2010). In area 2, the in  situ 
reaction revealed a second sub-clonal area of FANCD2 
mutant signals. Quantification of the sub-area 2 resulted 
in a mutation frequency of 6.7% (25/371 signals). In 
tumor K225, the areas 1 till 3 were investigated by in situ 
mutation detection (Fig. 4). The area 4 was not included 
as it did not contain any tumor tissue in the deeper sec-
tions of the FFPE-block. The area 4 was depleted for 
NGS analysis. All three remaining areas had a significant 
higher mutant allele frequency compared to non-neo-
plastic colon tissue (****p < 0.0001) (Fig. 3b). The total 
number of mutant signals per area were 22.6% (57/252 
signals; Mean 22.6%), 24.6% (50/203 signals; Mean 
22.4), 45.0% (115/255 signals; Mean 42.7%) for area 1 to 
3, respectively (Fig.  3b). Non-neoplastic colon tissue of 
Fig. 2  In situ mutation detection of FANCD2 wild-type and mutant 
transcripts in colorectal tumor tissue using padlock probes. a In situ 
location of transcripts in the four areas of interest. Each dot repre-
sents a transcript. Green dots are wild-type FANCD2; red dots are 
FANCD2 mutant transcripts. b Overview of the tissue in Hematox-
ylin and eosin staining. c Raw data image showing the locations of 
FANCD2 transcripts, magnified from the boxed areas in (a) area 4. 
Arrowheads depict wild-type FANCD2 (green) and mutant FANCD2 
(red) transcripts. Scale bars in (a) and (b) represent 1 mm and in (c) 
50 µm
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the same patient showed a total number of 0.79% (1/127; 
Mean 0.90%) KAT6A mutant signals (Fig. 3).
Discussion
The genetic landscape of six colorectal cancers with homo-
geneous morphology was evaluated by next-generation 
sequencing, pyro-sequencing, and a mRNA-based in  situ 
approach. We investigated if spatially separate tumor areas 
harboured heterogeneous distributions of mutated cancer 
cells. Our data reveal that a morphological homogeneous 
tumor can have a heterogeneous genetic landscape. Parallel 
to sequencing technologies, in situ mutation detection is a 
powerful tool to visualize intratumor heterogeneity within 
the architecture of a tumor.
NGS shows heterogeneity but needs confirmation 
by a second sequencing technology
NGS allows for the sequence analysis of many genes con-
currently. This leads to a much higher mutation detection 
rate than the traditional sequence analysis methods. In our 
study, up to 10 mutations could be identified in a single 
tumor using our comprehensive cancer panel, which is in 
accordance to our in house routine sequencing panel of 
colorectal cancers (data not shown). In comparison, “The 
Cancer Genome Atlas” (TCGA) study of colon and rectal 
Fig. 3  In situ mutation detec-
tion of FANCD2 and KAT6A 
mutations in a colorectal 
tumors. The relative muta-
tion frequency indicates the 
ratio between wild-type and 
mutant signals in the respec-
tive tissue. a Quantification of 
transcripts in tumor K386 and b 
in tumor K255. Each data point 
represents the mean mutation 
frequency of ten 20× field of 
views of the respective tumor 
area with each field of view 
comprises >80% tumor content 
(*p < 0.05, ***p < 0.001, and 
****p < 0.0001)























































































Fig. 4  In situ mutation detection of KAT6A wild-type and mutant 
transcripts in colon tumor tissue using padlock probes. a In situ loca-
tion of transcripts in the three areas of interest. b Overview of the tis-
sue in HE. Each dot represents a transcript. Green dots are wild-type 
KAT6A transcripts, red dots are KAT6A mutant transcripts. Scale 
bar represents 1 mm
Histochem Cell Biol 
1 3
cancers identified a mean number of 58 somatic mutations 
per tumor, but based on exome sequencing of non-hyper-
mutated tumors (Muzny et al. 2012). The allele frequencies 
of the detected mutations can, however, vary depending on 
multiple factors such as differences in PCR (or hybridiza-
tion) efficiency, sequencing artifacts, and also genetic heter-
ogeneity. Our data reveal that apparent genetic heterogene-
ity of tumor areas may also arise due to technical artifacts. 
Re-examination of mutation frequencies with an independ-
ent quantitative assay (pyro-sequencing) revealed techni-
cal artifacts as the reason for the heterogeneity detected by 
NGS in one case, but confirmed genetic heterogeneity in 
another. To reliably determine genetic heterogeneity, it is 
thus important to confirm NGS results with an independent 
method, at least for amplicon-based NGS technologies.
In situ mutation detection reveals heterogeneity
Our results are largely in agreement with a recent study by 
Hardiman et al. (2016). They investigated six rectal carci-
nomas using whole-exome sequencing followed by deep 
targeted sequencing with Ion Torrent and Oncoscan SNP 
arrays to assess copy number alterations and found sub-
stantial genetic heterogeneity (Hardiman et  al. 2016). In 
our approach, we included colon as well as rectal cancers 
and performed an in situ approach directly on the tumor tis-
sue. The mRNA-based in  situ approach by padlock probe 
technology allows direct visualisation of mutated tran-
scripts on tissue sections, and is referred to as in situ muta-
tion detection (Grundberg et al. 2013). The key strength of 
in situ mutation detection is the ability to localize mRNA 
transcripts directly in the tissue retaining the spatial infor-
mation. Furthermore, padlock probes are highly specific, 
allowing to differentiate sequences which differ by only 
a single base (e.g.: mutant vs wild type) (Larsson et  al. 
2010). In contrast, by applying next-generation sequencing, 
tissues are lysed to extract nucleic acids. Therefore, the his-
tological context of the tissue is lost. Moreover, the nucleic 
extracts represent several thousand cells and we have no 
understanding of where the different sub-clones reside 
within the tissue in a geographical sense. In situ mutation 
detection can close the gap between sequencing data and 
spatial information.
By in  situ mutation detection, we could clearly local-
ize FANCD2 wild type as well as mutated FANCD2 
transcripts to certain tumor areas with an increased muta-
tion allele frequency from area 1 to area 4. Remarkably, 
in  situ mutation detection could clearly identify a sub-
area in area 2 which contains the FANCD2 mutated cells 
(Fig.  2a). The morphological appearance of the sub-area 
in area 2 did not differ from that of other epithelial neo-
plastic areas of the respective tumor. Also KAT6A muta-
tion transcripts showed a higher number of mutant signals 
in area 3, indicating genetic heterogeneity. In general, wild-
type transcripts were detectable in the epithelial as well as 
the stromal compartments, whereas the mutant transcripts 
were exclusively localized to neoplastic epithelial tissue 
(apart from minor technically inherent background signals). 
This finding can be explained by the native in vivo protein 
function of the investigated targets KAT6A and FANCD2. 
The FANCD2 protein is involved in the pathway for DNA 
inter-strand crosslinks repair (Kozekov et  al. 2003), and 
is, therefore, not just expressed in the epithelium, but also 
in the stromal compartments of a tissue. The malfunction 
of this repair mechanism leads to accumulation of muta-
tions and is associated with the early cancer development 
and genomic instability (Reliene et  al. 2010; Shen et  al. 
2015; Michl et al. 2016). In general, genomic instability is 
considered to be the main driving force for genetic tumor 
heterogeneity. Genomic instability can be caused by many 
functional deficiencies, such as dysfunction of nucleotide 
repair mechanisms, poor telomere maintenance, deregu-
lated DNA replication, as well as defects in chromosomal 
segregation (Burrell et  al. 2013). KAT6A protein belongs 
to the family of histone acetyltransferases and is expressed 
in all tissues (Uhlen et  al. 2015) (Human Protein Atlas 
available from http://www.proteinatlas.org). KAT6A muta-
tions were widely distributed with the highest mutant allele 
frequency in area 3. The spatially distribution of hetero-
geneous mutation has mostly been envisioned as contigu-
ous. These contiguous, sub-clonal mutation areas would be 
owned to the expansions of sub-clonal mutations sweeping 
and replacing adjacent clones by virtue of their dominant 
proliferation. Recently Sottoriva et al. have questioned that 
assumption by providing evidence through mathemati-
cal modelling and confirmatory molecular analysis from 
actual tumor tissue, that sub-clonal heterogeneity in colo-
rectal cancer is rather dispersed in a “big bang” like fash-
ion across the tumor (Sottoriva et al. 2015). This expansive 
distribution would lead to sub-clonal areas corresponding 
in size to the age of the clone and—equally important—can 
be randomly distributed over different, spatially separate, 
and remote areas of invasive cancers with irregular topo-
graphic outlines of the sub-clones. By microdissection and 
subsequent molecular analysis, the authors were able to 
map out sub-clonal distributions strikingly reminiscent to 
the distributions visualized by in situ mutation detection in 
our study, especially in case of KAT6A mutations (Fig. 4), 
where the sub-clonal mutation shows multiple interspersed 
areas within (“folded into”) surrounding areas of KAT6A 
wild-type neoplastic epithelium. In case of FANCD2, the 
mutation bearing clones are predominantly located in com-
paratively small tumor areas (area 3, area 4, and focally in 
area 2). According to the big bang model, the FANCD2 
mutation is a late mutation in this tumor, as otherwise, it 
would be equally distributed over all tumor areas.
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Final conclusion
Genetic heterogeneity of morphologically homogene-
ous colorectal cancer seems to be a frequent event. Unu-
sual frequencies of mutated alleles not in keeping with the 
estimated tumor cell content of the areas sampled, can be 
attributed to sub-clonal genetic heterogeneity in a subset 
of cases. Although we analyzed only a limited number of 
samples, our study demonstrated that morphological tumor 
homogeneity does by no means exclude genetic tumor het-
erogeneity. It is safe to assume that genomic tumor het-
erogeneity is an underreported phenomenon, considering 
inherent methodological detection limits and analysis from 
only parts of the whole tumor in most cases. Sensitive and 
specific detection of tumor heterogeneity depend on care-
ful morphological and genetic correlations and an appropri-
ate selection of methodologies. To that end, in  situ muta-
tion analysis-in our opinion-readily deserves a place in this 
arsenal of options as it is inherently well suited to the task 
of bridging morphology with genomics.
Acknowledgements Open access funding provided by Medical 
University of Graz. We thank Andrea Thüringer and Iris Halbwedl 
for analyses done in the course of this project and Lanz Josefine for 
her technical assistance. Samples were provided by the Biobank of 
the Medical University Graz, Austria. This project was supported by 
the Start Funding of the Medical University Graz, Austria, and the 
Human Technology Interface Grants Sensor for Medical Applica-
tion A3-22.M-5/2012-21 and Tech_for_Med ABT08-22-T-7/2013-23 
awarded by the government of Styria, Austria.
Compliance with ethical standards 
Conflict of interest The authors declare that they have no conflict 
of interest.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted 
use, distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
Bedard PL, Hansen AR, Ratain MJ, Siu LL (2013) Tumour het-
erogeneity in the clinic. Nature 501:355–364. doi:10.1038/
nature12627
Blanco-Calvo M, Concha Á, Figueroa A et  al (2015) Colorectal 
cancer classification and cell heterogeneity: a systems oncol-
ogy approach. Int J Mol Sci 16:13610–13632. doi:10.3390/
ijms160613610
Bosman FT, World Health Organization, International Agency for 
Research on Cancer (2010) WHO classification of tumours of 
the digestive system, 4th edn. International Agency for Research 
on Cancer, Lyon
Burrell RA, McGranahan N, Bartek J, Swanton C (2013) The causes 
and consequences of genetic heterogeneity in cancer evolution. 
Nature 501:338–345. doi:10.1038/nature12625
Cingolani P, Platts A, Wang LL et al (2012) A program for annotating 
and predicting the effects of single nucleotide polymorphisms, 
SnpEff: SNPs in the genome of Drosophila melanogaster strain 
w1118; iso-2; iso-3. Fly (Austin) 6:80–92. doi:10.4161/fly.19695
de Bruin EC, McGranahan N, Mitter R et al (2014) Spatial and tempo-
ral diversity in genomic instability processes defines lung cancer 
evolution. Science 346:251–256. doi:10.1126/science.1253462
Diaz-Cano SJ (2012) Tumor heterogeneity: mechanisms and bases for 
a reliable application of molecular marker design. Int J Mol Sci 
13:1951–2011. doi:10.3390/ijms13021951
El-Heliebi A, Kroneis T, Wagner K, et al (2014) Resolving tumor het-
erogeneity: genes involved in chordoma cell development identi-
fied by low-template analysis of morphologically distinct cells. 
PLoS One 9:e87663. doi:10.1371/journal.pone.0087663
Fleming M, Ravula S, Tatishchev SF, Wang HL (2012) Colorectal 
carcinoma: pathologic aspects. J Gastrointest Oncol 3:153–173
Gerlinger M, Rowan AJ, Horswell S et al (2012) Intratumor heteroge-
neity and branched evolution revealed by multiregion sequenc-
ing. N Engl J Med 366:883–892. doi:10.1056/NEJMoa1113205
Grundberg I, Kiflemariam S, Mignardi M et al (2013) In situ muta-
tion detection and visualization of intratumor heterogeneity 
for cancer research and diagnostics. Oncotarget 4:2407–2418. 
doi:10.18632/oncotarget.1527
Hardiman KM, Ulintz PJ, Kuick RD et al (2016) Intra-tumor genetic 
heterogeneity in rectal cancer. Lab Invest 96:4–15
Heitzer E, Auer M, Gasch C et  al (2013) Complex tumor genomes 
inferred from single circulating tumor cells by array-CGH 
and next-generation sequencing. Cancer Res 73:2965–2975. 
doi:10.1158/0008-5472.CAN-12-4140
Kozekov ID, Nechev LV, Moseley MS et  al (2003) DNA interchain 
cross-links formed by acrolein and crotonaldehyde. J Am Chem 
Soc 125:50–61. doi:10.1021/ja020778f
Larsson C, Grundberg I, Söderberg O, Nilsson M (2010) In situ detec-
tion and genotyping of individual mRNA molecules. Nat Meth-
ods 7:395–397. doi:10.1038/nmeth.1448
Marusyk A, Almendro V, Polyak K (2012) Intra-tumour hetero-
geneity: a looking glass for cancer? Nat Rev 12:323–334. 
doi:10.1038/nrc3261
Michl J, Zimmer J, Buffa FM et al (2016) FANCD2 limits replication 
stress and genome instability in cells lacking BRCA2. Nat Struct 
Mol Biol. doi:10.1038/nsmb.3252
Misale S, Yaeger R, Hobor S et al (2012) Emergence of KRAS muta-
tions and acquired resistance to anti-EGFR therapy in colorectal 
cancer. Nature 486:532–536. doi:10.1038/nature11156
Misale S, Nicolantonio FD, Sartore-Bianchi A, et  al (2014) Resist-
ance to anti-EGFR therapy in colorectal cancer: from heteroge-
neity to convergent evolution. Cancer Discov doi:10.1158/2159-
8290.CD-14-0462
Muzny DM, Bainbridge MN, Chang K et  al (2012) Comprehensive 
molecular characterization of human colon and rectal cancer. 
Nature 487:330–337. doi:10.1038/nature11252
Nik-Zainal S, Alexandrov LB, Wedge DC et  al (2012a) Mutational 
processes molding the genomes of 21 breast cancers. Cell 
149:979–993. doi:10.1016/j.cell.2012.04.024
Nik-Zainal S, Van Loo P, Wedge DC et  al (2012b) The life his-
tory of 21 breast cancers. Cell 149:994–1007. doi:10.1016/j.
cell.2012.04.023
Ogino S, Goel A (2008) Molecular classification and correlates in 
colorectal cancer. J Mol Diagn JMD 10:13–27. doi:10.2353/
jmoldx.2008.070082
Reliene R, Yamamoto ML, Rao PN, Schiestl RH (2010) Genomic 
instability in mice is greater in Fanconi anemia caused by 
Histochem Cell Biol 
1 3
deficiency of Fancd2 than Fancg. Cancer Res 70:9703–9710. 
doi:10.1158/0008-5472.CAN-09-1022
Robinson JT, Thorvaldsdóttir H, Winckler W et  al (2011) Integra-
tive genomics viewer. Nat Biotechnol 29:24–26. doi:10.1038/
nbt.1754
Rothberg JM, Hinz W, Rearick TM et al (2011) An integrated semi-
conductor device enabling non-optical genome sequencing. 
Nature 475:348–352. doi:10.1038/nature10242
Shen Y, Lee Y-H, Panneerselvam J et  al (2015) Mutated Fanconi 
anemia pathway in non-Fanconi anemia cancers. Oncotarget 
6:20396–20403. doi:10.18632/oncotarget.4056
Siwetz M, Blaschitz A, El-Heliebi A, Hiden U, Desoye G, Huppertz 
B, Gauster M (2016) TNF-α alters the inflammatory secretion 
profile of human first trimester placenta. Lab Investig 96(4):428–
438. doi:10.1038/labinvest.2015.159
Sottoriva A, Kang H, Ma Z et al (2015) A Big Bang model of human 
colorectal tumor growth. Nat Genet 47:209–216. doi:10.1038/
ng.3214
Uhlen M, Fagerberg L, Hallstrom BM et al (2015) Proteomics. Tis-
sue-based map of the human proteome. Science 347:1260419. 
doi:10.1126/science.1260419
Wang K, Li M, Hakonarson H (2010) ANNOVAR: functional annota-
tion of genetic variants from high-throughput sequencing data. 
Nucleic Acids Res 38:e164. doi:10.1093/nar/gkq603
Weibrecht I, Lundin E, Kiflemariam S et al (2013) In situ detection 
of individual mRNA molecules and protein complexes or post-
translational modifications using padlock probes combined 
with the in situ proximity ligation assay. Nat Protoc 8:355–372. 
doi:10.1038/nprot.2013.006
Zhang J, Fujimoto J, Zhang J et  al (2014) Intratumor heterogeneity 
in localized lung adenocarcinomas delineated by multiregion 
sequencing. Science 346:256–259. doi:10.1126/science.1256930
